TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23357838

Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg 4 times daily for 6 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dalcetrapib alone (without probenecid)
Number of subjects: 20
Study: 16716060

Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 12
Study: 15679255

Group type: EXPERIMENTAL
Intervention: Gemcitabine (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and gemcitabine (specific details not mentioned)
Number of subjects: 0
Study: 11087215

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 8
Study: 8799512

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg sublingual
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF) 10 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg orally twice daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF) 20 mg twice daily
Number of subjects: 23
Study: 1459316

Group type: EXPERIMENTAL
Intervention: benazepril (10 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 3977556

Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 0
Study: 30860653

Group type: EXPERIMENTAL
Intervention: ConquerFear intervention
Number of subjects: 222

Group type: COMPARATOR
Intervention: Active control group (relaxation training)
Number of subjects: 222
Study: 28730753

Group type: EXPERIMENTAL
Intervention: AIR score-based algorithm
Number of subjects: 2639

Group type: COMPARATOR
Intervention: Routine imaging
Number of subjects: 2639

Group type: COMPARATOR
Intervention: Selective imaging after clinical reassessment
Number of subjects: 2639
Study: 25701070

Group type: EXPERIMENTAL
Intervention: Coronary angiography before CEA (Group A)
Number of subjects: 426

Group type: COMPARATOR
Intervention: No coronary angiography before CEA (Group B)
Number of subjects: 426
Study: 23536611

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 11897
Study: 20647958

Group type: EXPERIMENTAL
Intervention: Keishibukuryogan
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Kamishoyosan
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study: 18823799

Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty (TEA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Open reduction-internal fixation (ORIF)
Number of subjects: 42
Study: 17211497

Group type: EXPERIMENTAL
Intervention: Strength training plus standard care (ST group)
Number of subjects: 62
Study: 15931690

Group type: EXPERIMENTAL
Intervention: Oral famciclovir 250 mg twice daily
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study: 11789262

Group type: EXPERIMENTAL
Intervention: Composite Taixian tablet (CTXT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tripterygium hypoglaucum tablet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Polyactin‐A tablet
Number of subjects: 60
Study: 9081688

Group type: EXPERIMENTAL
Intervention: 2 mg/d micronized 17 beta-estradiol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1608523

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg bid im starting one day before surgery and continuing until the 7th postoperative day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Calcium heparin (5000 IU bid sc starting two hours before surgery and continuing likewise for 7 days)
Number of subjects: 81
Study: 3936097

Group type: EXPERIMENTAL
Intervention: Valerian extract (450 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Valerian extract (900 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31164265

Group type: COMPARATOR
Intervention: Tamoxifen (T)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Letrozole (L)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Zoledronic acid plus Letrozole (ZL)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Zoledronic acid (ZL) vs Tamoxifen (T)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Letrozole (L) vs Tamoxifen (T)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Zoledronic acid (ZL) vs Letrozole (L)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Grade 3–4 side effects
Number of subjects: 1065
Study: 29874375

Group type: COMPARATOR
Intervention: Standard fluorouracil-based preoperative chemoradiotherapy (CRT) alone (control arm)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Oxaliplatin followed by TME and adjuvant chemotherapy (experimental arm)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: TME plane quality (mesorectal, intramesorectal, muscularis propria)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: TME plane assessment by pathologists
Number of subjects: 1236
Study: 27471048

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening (LDCT)
Number of subjects: 4037

Group type: COMPARATOR
Intervention: Usual care (no screening)
Number of subjects: 4037
Study: 24648285

Group type: EXPERIMENTAL
Intervention: Web-based mother-centered interventions for obesity prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22410207

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 340
Study: 20338894

Group type: EXPERIMENTAL
Intervention: Monitoring of intracranial pressure (ICP) variability during the first 48 hours
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Moving averages display in bedside monitoring
Number of subjects: 38
Study: 18710726

Group type: EXPERIMENTAL
Intervention: Standard treatment plus placebo, oxybutynin, or bladder training with online feedback (urge syndrome)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Standard treatment plus pelvic floor training with online feedback (dysfunctional voiding)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard treatment (urge syndrome and dysfunctional voiding)
Number of subjects: 202
Study: 15972357

Group type: EXPERIMENTAL
Intervention: Disease-modifying anti-rheumatic drug (DMARD) therapy
Number of subjects: 366

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 366

Group type: COMPARATOR
Intervention: 5-year assessment
Number of subjects: 366
Study: 12133434

Group type: EXPERIMENTAL
Intervention: 6-MWT exercise training (twice a day for 8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6-MWT exercise training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (routine medication only)
Number of subjects: 60
Study: 10613616

Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 0.25 mg levonorgestrel once daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7784306

Group type: EXPERIMENTAL
Intervention: Brand 1 (Biltricide) at full dose (40 mg kg‐1)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Brand 2 (Distocide) at full dose (40 mg kg‐1)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Brand 1 (Biltricide) at half dose (20 mg kg‐1)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Brand 2 (Distocide) at half dose (20 mg kg‐1)
Number of subjects: 506
Study: 2019862

Group type: EXPERIMENTAL
Intervention: Cefodizime (2 g, once a day, i.v.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg, twice a day, p.o.)
Number of subjects: 40
Study: 6924538

Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin (3 g)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Two-week amoxicillin treatment (250 mg three times a day)
Number of subjects: 388
Study: 30579065

Group type: EXPERIMENTAL
Intervention: Video glasses
Number of subjects: 23
Study: 28233009

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham Kinesio taping
Number of subjects: 21
Study: 25043339

Group type: EXPERIMENTAL
Intervention: Genetic Risk Score 63 (GRS63)
Number of subjects: 8067

Group type: EXPERIMENTAL
Intervention: Genetic Risk Score 16 (GRS16)
Number of subjects: 8067

Group type: COMPARATOR
Intervention: Base model (age, weight, height)
Number of subjects: 8067

Group type: COMPARATOR
Intervention: BMD-adjusted models
Number of subjects: 8067

Group type: EXPERIMENTAL
Intervention: Net reclassification improvements with GRSs
Number of subjects: 8067
Study: 23444094

Group type: EXPERIMENTAL
Intervention: BEX Runner palm cooling device
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no palm cooling)
Number of subjects: 12
Study: 21319291

Group type: EXPERIMENTAL
Intervention: Gabapentin treatment
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Opioids treatment
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 498

Group type: COMPARATOR
Intervention: Vincristine dose
Number of subjects: 498
Study: 20084980

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17972431

Group type: EXPERIMENTAL
Intervention: Daily Mutual Caring Interactions (DMCI) scale
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: SF-36v2
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: DMCI constructs
Number of subjects: 525
Study: 15139502

Group type: EXPERIMENTAL
Intervention: Cooked green banana (n = 19)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pectin (n = 17)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Rice diet alone (n = 21)
Number of subjects: 57
Study: 11924916

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 0
Study: 9021442

Group type: EXPERIMENTAL
Intervention: tolbutamide R.A.N.
Number of subjects: 22

Group type: COMPARATOR
Intervention: rastianon Hoechst
Number of subjects: 22
Study: 7938234

Group type: EXPERIMENTAL
Intervention: Phenylalanine (up to 10.08 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspartame (high doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alanine (designated as placebo)
Number of subjects: 0
Study: 3203045

Group type: EXPERIMENTAL
Intervention: Nisoldipine (5 mg day-1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg day-1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31313402

Group type: EXPERIMENTAL
Intervention: XR-NTX injection every 4 weeks
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo injection every 4 weeks
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 29584518

Group type: COMPARATOR
Intervention: Control (CON, n=7), all sets with 10RM load
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 5% load reduction (RED 5, n=7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10% load reduction (RED 10, n=7)
Number of subjects: 21
Study: 28410787

Group type: EXPERIMENTAL
Intervention: 0.2% NTG ointment applied at the anal canal twice daily for 8 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Classical conservative therapy (sitz bath, stool softener, local anesthetic)
Number of subjects: 105
Study: 26180222

Group type: EXPERIMENTAL
Intervention: Tailored intervention (Aurora)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Enhanced standard care (ESC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Both groups received 8 weeks of nicotine replacement therapy (NRT) patch
Number of subjects: 302
Study: 23549909

Group type: EXPERIMENTAL
Intervention: OM 40/AML 10/HCTZ 25 mg triple-combination treatment
Number of subjects: 2492
Study: 21912659

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 18349202

Group type: EXPERIMENTAL
Intervention: 40 mg of dexamethasone i.v. before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo i.v. before surgery
Number of subjects: 50
Study: 16339480

Group type: EXPERIMENTAL
Intervention: Additional vascular risk factors for eligibility in stroke prevention trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional vascular risk factors
Number of subjects: 0
Study: 14703215

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (0.05%) mouth rinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) mouth rinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triclosan (0.3%) mouth rinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no mouth rinse)
Number of subjects: 60
Study: 10981070

Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium-channel blockers
Number of subjects: 0
Study: 8877026

Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ketoconazole (200 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim)
Number of subjects: 10
Study: 1676621

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 6670581

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 90

Group type: COMPARATOR
Intervention: melitracen-flupentixol
Number of subjects: 90
Study: 3981325

Group type: EXPERIMENTAL
Intervention: sucrose 1.75 gm/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo (aspartame in equivalent sweetness)
Number of subjects: 16
Study: 29650949

Group type: EXPERIMENTAL
Intervention: Monoclonal IgG antibodies against Fel d 1 (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional SIT (not specified in detail)
Number of subjects: 0
Study: 27633841

Group type: EXPERIMENTAL
Intervention: Eyes that subsequently developed PVD (1.81 ± 0.61 %W; P = .146)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Following PVD
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients who chose limited vitrectomy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: After vitrectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control fellow eyes
Number of subjects: 28
Study: 24714359

Group type: COMPARATOR
Intervention: Erlotinib therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DC/CIK plus erlotinib
Number of subjects: 54
Study: 22588140

Group type: EXPERIMENTAL
Intervention: 75NC007 intravaginal device
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study: 20822474

Group type: EXPERIMENTAL
Intervention: Acupressure at acupuncture point spleen 6 (SP6) on both legs during contractions for 30 minutes
Number of subjects: 212

Group type: COMPARATOR
Intervention: Light touch at SP6 on both legs during the same period
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 212
Study: 18377647

Group type: EXPERIMENTAL
Intervention: Eurythmy therapy (EYT) as an add-on treatment
Number of subjects: 898

Group type: COMPARATOR
Intervention: Eurythmy therapy (EYT)
Number of subjects: 898
Study: 16153010

Group type: EXPERIMENTAL
Intervention: Theophylline ethanoate of piperazine suppositories (Minophylline 500 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous (IV) theophylline ethanoate of piperazine (Minophylline ampoules 500 mg)
Number of subjects: 24
Study: 12502668

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg/day
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg/day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Sibutramine (both doses)
Number of subjects: 195
Study: 10228287

Group type: EXPERIMENTAL
Intervention: Polyethylene wrap applied immediately at birth
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-wrap group (control)
Number of subjects: 62
Study: 8911510

Group type: EXPERIMENTAL
Intervention: Autologous ex vivo activated T‐lymphocytes and cimetidine (ALT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall treatment with ALT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with elevated alkaline phosphatase (AP) levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with normal alkaline phosphatase (AP) levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with bone metastases
Number of subjects: 90
Study: 1801563

Group type: EXPERIMENTAL
Intervention: Urge scripts (imagery scripts with explicit descriptions of smoking urge situations)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Neutral scripts (imagery scripts devoid of explicit urge content)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Urge scripts
Number of subjects: 66

Group type: COMPARATOR
Intervention: Neutral scripts
Number of subjects: 66
Study: 6847217

Group type: EXPERIMENTAL
Intervention: Unilateral UV-B phototherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated side
Number of subjects: 20
Study: 31740017

Group type: EXPERIMENTAL
Intervention: Electronic Cigarettes (EC) with nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic Cigarettes (EC) without nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobacco Cigarettes (TC)
Number of subjects: 0
Study: 29426261

Group type: EXPERIMENTAL
Intervention: Blue dye‐guided lymph channel ligation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard inguinal lymphadenectomy without blue dye guidance)
Number of subjects: 0
Study: 26993261

Group type: EXPERIMENTAL
Intervention: Early initiation of renal replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late initiation of renal replacement therapy
Number of subjects: 0
Study: 24332419

Group type: EXPERIMENTAL
Intervention: Newer-generation drug-eluting stents (everolimus-eluting stent or biolimus A9-eluting stent)
Number of subjects: 2665

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2665
Study: 22513012

Group type: EXPERIMENTAL
Intervention: Optimal Health Program (OHP), a nine-session self-management intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine care plus Optimal Health Program (OHP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 0
Study: 20375277

Group type: EXPERIMENTAL
Intervention: Low anticoagulant 2-O,3-O-desulfated heparin (ODSH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 17493184

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided from admission to discharge by a specialist clinical pharmacist
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 203
Study: 17315407

Group type: EXPERIMENTAL
Intervention: Rapid opioid detoxification (ROD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonidine-assisted detoxification (CD)
Number of subjects: 80
Study: 11486702

Group type: COMPARATOR
Intervention: Cyclophosphamide 600 mg/m2 plus carboplatin 300 mg/m2 (conventional dose)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 plus carboplatin 600 mg/m2 (intensive dose)
Number of subjects: 91
Study: 9917680

Group type: EXPERIMENTAL
Intervention: Fluted 10-mm diameter femoral intramedullary alignment rod
Number of subjects: 48

Group type: COMPARATOR
Intervention: Round 10-mm diameter femoral intramedullary alignment rod
Number of subjects: 48
Study: 7798466

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Imipramine (IMI)
Number of subjects: 48
Study: 3053320

Group type: EXPERIMENTAL
Intervention: Absolute alcohol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Polidocanol
Number of subjects: 11
Study: 1110274

Group type: EXPERIMENTAL
Intervention: Relaxed wakefulness condition (subjects instructed to relax but stay awake)
Number of subjects: 20
Study: 31465092

Group type: EXPERIMENTAL
Intervention: AAV2-REP1 gene therapy (0.1-mL subretinal injection of 10^11 genome particles)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control eyes (untreated)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AAV2-REP1 gene therapy
Number of subjects: 6
Study: 27694534

Group type: EXPERIMENTAL
Intervention: Greater income
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Greater pain interference
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Less pain interference with lower levels of depressive symptoms
Number of subjects: 202
Study: 26969273

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis (TSP)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study: 24954781

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Sequential chemoimmunotherapy (chemotherapy with sequential GV1001)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Concurrent chemoimmunotherapy (chemotherapy with concurrent GV1001)
Number of subjects: 1062
Study: 22224877

Group type: EXPERIMENTAL
Intervention: Community-focused interventions (e.g., school-based programs, community coalitions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Programs using electronic media and phone links
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policy and systems changes through community coalitions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparisons among proven asthma control interventions
Number of subjects: 0
Study: 19008007

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus insulin (INS+RSG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Insulin alone (INS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sulfonylureas (SUs)
Number of subjects: 54
Study: 18219838

Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Indacaterol 800 microg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 144